Browse the evidence

GLP-1 receptor agonists reduce blood pressure and improve lipid profiles (LDL-C, triglycerides), contributing to the stabilization of atherosclerotic plaques and reduced cardiovascular risk.

GLP-1RAs help lower blood pressure and improve cholesterol levels, which protects your arteries from plaque buildup. This is an added benefit beyond blood sugar control, helping to prevent heart attacks and strokes.

GLP-1 receptor agonists exhibit protective effects on the kidneys by reducing the decline in estimated glomerular filtration rate (eGFR) and delaying the onset of proteinuria in patients with Type 2 Diabetes.

GLP-1RAs help protect your kidneys from damage caused by diabetes. They slow down the loss of kidney function and reduce protein leakage into the urine, which is crucial for long-term kidney health.

Semaglutide increases the risk of biliary disease (cholelithiasis), which is a class effect of GLP-1 receptor agonists, likely due to rapid weight loss.

Be aware that semaglutide increases the risk of gallbladder problems like gallstones. This risk is associated with the rapid weight loss the drug causes. Report any severe abdominal pain, especially in the upper right side, to your doctor immediately.

In obese individuals with chronic short sleep (<6.5 hours/night), an evening chronotype is associated with higher cardiovascular risk, characterized by increased stress hormones (ACTH, epinephrine), higher resting heart rate, and a higher prevalence of sleep apnea compared to morning types.

If you are obese and consistently sleep less than 6.5 hours, being an 'evening person' significantly increases your risk for sleep apnea and stress-related cardiovascular strain. Prioritizing sleep extension and managing evening light exposure may help mitigate these specific hormonal and cardiovascular risks.

In obese short-sleepers, an evening chronotype is associated with altered eating patterns, specifically consuming more calories after 8 PM, fewer eating occasions, and larger portion sizes, which correlates with lower HDL-cholesterol levels.

For obese individuals sleeping less than 6.5 hours, being an evening type often means eating larger, less frequent meals and consuming more calories late at night. This pattern is linked to lower HDL (good) cholesterol. Try to shift eating earlier in the day and avoid large late-night meals.

Chronic exercise significantly improves sleep quality by increasing total sleep time and reducing time awake after sleep onset, whereas acute exercise effects on slow-wave sleep are inconsistent and depend heavily on timing and intensity.

Prioritize consistent, chronic exercise over specific timing for sleep benefits. While acute effects vary, long-term habitual exercise reliably improves total sleep time and reduces nighttime awakenings. If you exercise late, do not worry excessively about sleep disruption; the body adapts, and quality is often preserved.

PPAR-gamma agonists (thiazolidinediones) reduce liver fat and increase adiponectin levels, whereas metformin does not significantly reduce liver fat content.

If you have fatty liver, standard diabetes medication like metformin may not reduce the liver fat itself, whereas PPAR-gamma agonists (like pioglitazone or rosiglitazone) can significantly reduce it, similar to the effect of moderate weight loss. Consult a doctor for medication options.

Visceral adipose tissue (VAT) is strongly associated with insulin resistance, dyslipidemia, and hypertension, independent of subcutaneous fat and BMI, due to its pro-inflammatory secretory profile.

Where you store fat matters more than how much you weigh. Reducing visceral fat through diet and exercise is critical for lowering the risk of diabetes and heart disease, even if your overall weight doesn't change drastically.

Dietary intake of polyunsaturated fatty acids (PUFA) is positively associated with fasting adiponectin levels, while saturated fatty acid (SFA) intake is negatively associated, suggesting that dietary fat quality modulates adiponectin secretion.

To support higher adiponectin levels, NASH patients should focus on increasing their intake of polyunsaturated fatty acids (PUFA) and reducing saturated fatty acids (SFA). This shift in dietary fat quality, rather than just total fat reduction, is associated with higher fasting adiponectin levels.

DHA supplementation (600 mg/day for 16 weeks) significantly increases sleep duration and reduces night wakings in children.

For children with sleep issues, consider a DHA supplement of 600 mg per day for at least 16 weeks. This has been shown in an RCT to increase total sleep time by nearly an hour and reduce night wakings.

Vitamin D deficiency is associated with a higher risk of sleep disorders, including poor sleep quality, short sleep duration, and sleepiness.

Ensure you have adequate vitamin D levels, as deficiency is linked to poor sleep quality, short sleep duration, and sleepiness. Consider supplementation if you have limited sun exposure or dietary intake.

High-glycemic-index (GI) carbohydrate foods worsen metabolic syndrome factors (glucose, triglycerides, HDL, fibrinolysis), whereas high-fiber, low-GI foods do not induce these detrimental effects.

Choose carbohydrates that are high in fiber and have a low glycemic index (e.g., vegetables, legumes, whole grains). Avoid high-GI carbs (e.g., white bread, sugary drinks) as they worsen metabolic health. You do not need to eliminate carbs entirely.

In very old adults (72-95 years), high percent body fat is strongly associated with physical disability, whereas low skeletal muscle mass is not associated with disability.

For adults over 70, maintaining a healthy body fat percentage appears to be more critical for preventing physical disability than simply having high muscle mass. While resistance training is beneficial, excessive fat accumulation significantly increases the risk of disability, likely due to mechanical burden and chronic disease links. Focus on body composition (reducing fat) rather than just muscle size.

Sarcopenic obesity, defined as the concurrent presence of low muscle mass and high adiposity, has a compounding negative impact on health outcomes and is common in chronic disease populations.

For obese patients, especially those with chronic diseases, focusing solely on weight loss may be counterproductive. It is crucial to assess and preserve muscle mass through targeted interventions like resistance training and adequate protein intake, as sarcopenic obesity is associated with worse outcomes than obesity alone.

Muscle quality, assessed by muscle attenuation (fat infiltration) via CT or MRI, is an independent and emerging prognostic indicator for survival and outcomes, often more predictive than muscle mass alone.

For patients undergoing CT or MRI scans, muscle quality (attenuation) should be assessed alongside muscle mass, as it is a strong predictor of survival and outcomes. This is particularly relevant for cancer, critical illness, and liver disease patients. Future clinical practice should aim to make muscle quality assessment more routine.

Using individualized Estimated Energy Requirements (EER) based on self-reported physical activity provides a more accurate and sensitive estimation of dietary under-reporting than population-based cut-offs (like the Goldberg method) which assume a sedentary lifestyle.

When analyzing dietary data for health or weight outcomes, do not rely solely on simple population cut-offs to identify 'under-reporters.' Instead, use individualized Estimated Energy Requirements (EER) that incorporate each person's specific physical activity level. This approach reduces bias, particularly for active individuals, and provides a more accurate picture of true energy intake relative to expenditure.

Overweight and obese individuals significantly under-report their energy intake more than lean individuals, with under-reporting estimated at 39% higher in obese men and 57% higher in obese women compared to their lean counterparts.

Be aware that dietary self-reports from overweight and obese individuals tend to underestimate actual calorie intake significantly more than those from lean individuals. When using self-reported data for health assessments, apply corrections for under-reporting based on BMI and activity level to avoid misjudging energy balance.

Crohn's disease patients in clinical remission exhibit frequent micronutrient deficiencies (specifically vitamins C, copper, niacin, and zinc) despite adequate macronutrient and energy intake.

Even if you have Crohn's disease and are currently in remission with a normal appetite, you are likely deficient in key vitamins and minerals. You need specific blood tests for Vitamin C, Copper, Niacin, and Zinc, and likely supplementation, because standard food intake is not enough to maintain these levels.

Probiotic supplementation in overweight or obese adults produces a statistically significant but clinically small reduction in body weight, BMI, and fat percentage compared to placebo.

If you are overweight or obese, adding probiotics may help you lose a tiny amount of extra weight (about 0.6 kg) compared to not taking them. Do not rely on probiotics for weight loss; focus on diet and exercise first, as the probiotic effect is negligible in isolation.

Higher intake of heme iron (found in meat) is significantly associated with an increased risk of developing type 2 diabetes, whereas total, non-heme, or supplemental iron intakes are not.

If you are concerned about type 2 diabetes risk, the source of your iron matters. High intake of heme iron (from meat) is linked to higher risk, while total, non-heme, or supplemental iron are not. You do not need to eliminate all iron sources, but being mindful of high heme iron intake may be a prudent dietary strategy.

Higher body iron stores, as measured by ferritin or soluble transferrin receptor (sTfR), are significantly associated with an increased risk of type 2 diabetes.

If you have high ferritin levels, it may indicate higher body iron stores, which is linked to a greater risk of type 2 diabetes. This risk is independent of inflammation in many cases. Discussing your ferritin levels with a healthcare provider can help determine if dietary changes to reduce heme iron intake are appropriate.

Chronic insomnia causes reversible prefrontal cortical hypoactivation (specifically in the medial and inferior prefrontal cortex) during daytime cognitive tasks, which can be restored through nonpharmacological sleep therapy.

If you suffer from chronic insomnia, nonpharmacological sleep therapy (combining cognitive behavioral therapy, sleep restriction, bright light, and temperature manipulation) over 6 weeks can restore normal prefrontal brain activation associated with cognitive function. This recovery is reversible and does not require medication.

A low-dose, self-administered mindfulness intervention (approx. 10 minutes daily for 2 weeks) significantly improves sleep quality and sleep duration in employees, but does not significantly improve psychological detachment from work.

If you are an employee struggling with sleep, try a 10-minute daily mindfulness practice for two weeks. You do not need a class or a trainer. Use audio-guided exercises like body scans or breathing spaces. This low-dose approach has been shown to improve both how well you sleep and how long you sleep, even if it doesn't stop you from thinking about work.

Pitolisant (5-20 mg/day) significantly reduces self-reported excessive daytime sleepiness and fatigue in patients with moderate-to-severe obstructive sleep apnea who refuse or are non-adherent to CPAP therapy, without improving objective maintenance of wakefulness.

If you have moderate to severe sleep apnea but cannot or will not use CPAP, pitolisant (5-20mg daily) can significantly reduce your daytime sleepiness and fatigue. It does not fix the breathing pauses or objectively improve your ability to stay awake in a lab test, but it does make you feel less sleepy and improves your quality of life. It is generally safe with side effects similar to placebo.